Literature DB >> 19568151

Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study.

Rosebud O Roberts1, Yonas E Geda, David S Knopman, Ruth H Cha, Bradley F Boeve, Robert J Ivnik, Vernon Shane Pankratz, Eric G Tangalos, Ronald C Petersen.   

Abstract

The metabolic syndrome (MetS) is more strongly associated with cognitive impairment in the presence of inflammation. This suggests that the association of MetS with mild cognitive impairment (MCI) may vary with the etiology and the subtype of MCI. This study investigated the association between MetS with or without inflammation and MCI [amnestic (a-MCI) and nonamnestic (na-MCI)]. We studied a randomly selected sample of 1969 participants (ages 70 to 89 y) from Olmsted County, MN, using the Clinical Dementia Rating Scale, a neurologic evaluation, and neuropsychologic testing. Data for participants were reviewed for a diagnosis of normal cognition, MCI, or dementia. Clinical components of MetS were ascertained by interview and confirmed from the medical records; biochemical measurements were assayed from a blood draw. We compared 88 na-MCI cases and 241 a-MCI cases with 1640 cognitively normal participants. MetS was not associated with either na-MCI or a-MCI. High C-reactive protein (CRP; highest tertile vs lowest tertile) was associated with na-MCI [odds ratio (OR)=1.85; 95% confidence interval (CI)=1.05, 3.24] but not with a-MCI, after adjusting for sex, age, and years of education. The combination of MetS and high CRP (compared to no MetS and lowest CRP tertile) was associated with na-MCI (OR=2.31; 95% CI=1.07, 5.00), but not with a-MCI (OR=0.96; 95% CI=0.59, 1.54). The combined presence of MetS and high levels of inflammation is associated with na-MCI in this elderly cohort, and suggests etiologic differences in MCI subtypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19568151      PMCID: PMC2837096          DOI: 10.1097/WAD.0b013e3181a4485c

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  38 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

3.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

Review 4.  Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view.

Authors:  Peter W F Wilson
Journal:  Endocrinol Metab Clin North Am       Date:  2004-09       Impact factor: 4.741

5.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.

Authors:  M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  BMJ       Date:  2001-06-16

6.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

Authors:  D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  An 18-year follow-up of overweight and risk of Alzheimer disease.

Authors:  Deborah Gustafson; Elisabet Rothenberg; Kaj Blennow; Bertil Steen; Ingmar Skoog
Journal:  Arch Intern Med       Date:  2003-07-14

9.  Contribution of metabolic syndrome components to cognition in older individuals.

Authors:  Miranda G Dik; Cees Jonker; Hannie C Comijs; Dorly J H Deeg; Astrid Kok; Kristine Yaffe; Brenda W Penninx
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

10.  Low blood pressure and the risk of dementia in very old individuals.

Authors:  J Verghese; R B Lipton; C B Hall; G Kuslansky; M J Katz
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

View more
  29 in total

1.  Metabolic syndrome and localization of white matter hyperintensities in the elderly population.

Authors:  Florence Portet; Adam M Brickman; Yaakov Stern; Nikolaos Scarmeas; Jordan Muraskin; Frank A Provenzano; Claudine Berr; Alain Bonafé; Sylvaine Artero; Karen Ritchie; Tasnime N Akbaraly
Journal:  Alzheimers Dement       Date:  2012-06-06       Impact factor: 21.566

2.  Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats.

Authors:  Steven D Brooks; Evan DeVallance; Alexandre C d'Audiffret; Stephanie J Frisbee; Lawrence E Tabone; Carl D Shrader; Jefferson C Frisbee; Paul D Chantler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

Review 3.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

Review 4.  Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?

Authors:  Juan F Codocedo; Juvenal A Ríos; Juan A Godoy; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

Review 5.  Vascular disease and dementias: paradigm shifts to drive research in new directions.

Authors:  Mitchel A Kling; John Q Trojanowski; David A Wolk; Virginia M Y Lee; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2012-11-22       Impact factor: 21.566

6.  A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment.

Authors:  Balwinder Singh; Michelle M Mielke; Ajay K Parsaik; Ruth H Cha; Rosebud O Roberts; Paul D Scanlon; Yonas E Geda; Teresa J Christianson; V Shane Pankratz; Ronald C Petersen
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

7.  Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging.

Authors:  V Shane Pankratz; Rosebud O Roberts; Michelle M Mielke; David S Knopman; Clifford R Jack; Yonas E Geda; Walter A Rocca; Ronald C Petersen
Journal:  Neurology       Date:  2015-03-18       Impact factor: 9.910

Review 8.  Heterogeneity of Neuropsychological Impairment in HIV Infection: Contributions from Mild Cognitive Impairment.

Authors:  Kathryn N Devlin; Tania Giovannetti
Journal:  Neuropsychol Rev       Date:  2017-05-24       Impact factor: 7.444

9.  Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.

Authors:  Debra Lyon; Lynne Elmore; Noran Aboalela; Jacqueline Merrill-Schools; Nancy McCain; Angela Starkweather; R K Elswick; Colleen Jackson-Cook
Journal:  Biol Res Nurs       Date:  2013-04-11       Impact factor: 2.522

10.  Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study.

Authors:  Cadman L Leggett; Eric M Nelsen; Jianmin Tian; Cathy B Schleck; Alan R Zinsmeister; Kelly T Dunagan; G Richard Locke; Kenneth K Wang; Nicholas J Talley; Prasad G Iyer
Journal:  Mayo Clin Proc       Date:  2013-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.